Clin2
NCT07083206Possibly a fitRecruiting

Pitavastatin/ezetimibe for high cholesterol

HypercholesterolemiaDyslipidemias

Part of Hormones & metabolism clinical trials.

This trial tests a combination pill of two cholesterol-lowering medicines (pitavastatin and ezetimibe) in adults who have been taking either atorvastatin or rosuvastatin for at least 3 months. It aims to see if switching to this new combination is safe and effective.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
4,500 people
Ages
19 years and older
Study type
Observational

Who can take part

  • Age 19 or older
  • Diagnosed with high cholesterol
  • Currently on atorvastatin or rosuvastatin (alone) for at least 3 months without dose changes
  • Doctor has decided to switch you to the pitavastatin/ezetimibe combination pill
  • Blood test results within the past year showing cholesterol and liver/kidney function
  • Able to give written consent to participate
  • No known allergy to any ingredient in the study drug
  • No active liver disease or unexplained high liver enzymes
  • No severe liver problems, bile duct block, or bile flow issues
  • Not taking cyclosporine (an immune-suppressing medicine)
  • No diagnosis of myopathy (a muscle disease)
  • Not pregnant, breastfeeding, or planning to become pregnant
  • No genetic conditions like galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07523971Recruiting
Pitavastatin/Ezetimibe for High Cholesterol and Metabolic Syndrome

This study watches how well a combination cholesterol medication (pitavastatin and ezetimibe) works in people who have high cholesterol and metabolic syndrome (a cluster of health issues including high blood pressure, blood sugar, and cholesterol). You'll be monitored over time to see if the medication helps and is safe for you.

Daejeon
NCT05705804Recruiting
Comparing statins and ezetimibe for heart patients with metabolic syndrome

This trial tests if pitavastatin alone or with ezetimibe affects blood sugar differently than atorvastatin in people who have heart or blood vessel disease and metabolic syndrome but do not have diabetes.

Seoul
NCT06186037Recruiting· Phase 4
Lower-dose combo vs. higher-dose alone for heart artery disease

This trial compares a lower-dose cholesterol pill (rosuvastatin plus ezetimibe) to a higher-dose version of just rosuvastatin for people with mild to moderate heart artery blockages who have not had a stent or bypass. It aims to see which approach works better and is safer.

Suwon, Gyeonggi-do
NCT05845424Recruiting· Phase 4
High-intensity cholesterol pills for people with silent calcium

This trial studies whether high-intensity statin plus ezetimibe can improve heart health in people who do not have symptoms but have calcium buildup in their heart arteries. It may help lower cholesterol and reduce future heart risks for the right participants.

Seoul
NCT07524101Recruiting
Statin and Ezetimibe for Heart Disease and Kidney Disease

This trial tests whether taking a moderate-strength statin (cholesterol-lowering drug) plus ezetimibe (another cholesterol medicine) together helps protect the heart and kidneys in people who have both chronic kidney disease and established heart disease or stroke history.

Seoul
NCT07474649Not yet recruiting· Phase 3
Study of a cholesterol-lowering combination pill for patients without heart events

This trial tests a triple therapy pill (bempedoic acid, ezetimibe, and a high-intensity statin) in patients who have extensive plaque in their heart arteries but have never had a heart attack or stroke. It aims to see if this combination can further lower cholesterol and prevent future problems.

Berlin

Hear when a new Hypercholesterolemia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.